CTOs on the Move

ALLETE PHARMACEUTICALS

www.alletepharm.com

 
ALLETE PHARMACEUTICALS is a Danville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.alletepharm.com
  • 4115 Blackhawk Plaza Cir Ste 100
    Danville, CA USA 94506
  • Phone: 925.736.8402

Executives

Name Title Contact Details

Similar Companies

Piramal Critical Care

Piramal Critical Care is a Boise, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Family Guidance Centers

Since 1980, we have been offering our clients experienced and compassionate clinical care, which gives us the distinction of having served the people of Chesterfield longer than any other private mental health group practice in the county. Our staff of...

Caribbean Clinical Research ASsociates

Caribbean Clinical Research ASsociates is a East Orange, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ZO Skin Health

ZO® Skin Health provides a comprehensive range of solutions that will restore skin to a healthy state. From correcting sun damage and pigmentation to acne and aging, ZO® offers a simple, systematic approach to creating and maintaining healthy skin.

Unum Therapeutics

Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers.   Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.